Medicine and Health Sciences Commons^™

Regulatory Issues Concerning The Preclinical Testing Of Synthetic Peptides, Vamsi Vardhan Niraghatam

Master's Theses and Doctoral Dissertations

Any new drug or biological product undergoes rigorous testing in animals and humans for review by the United States Food and Drug Administration (FDA) before it becomes available for human use. A sponsor files an investigational new drug (IND) application with the FDA with supporting animal data, after which testing is continued with humans. There is sufficient guidance from the FDA on new small molecules and biological products as to which preclinical studies are to be conducted. Synthetic peptides present a unique scenario in which a case-by-case approach is needed for the conduct of preclinical studies. For peptides containing components …